Mgnesium 10% Injection (Magnesium Sulfate Hydrate)

Adult administration

Hypomagnesemic convulsions: Administer 1 to 2 g of magnesium sulfate intravenously (4.05 to 8.1 mmol). Eclampsia seizures: Administer 4 to 5 g of this medication intravenously over 10 minutes (16.2 to 20.25 mmol). Prevention of uterine contractions: Administer 4 g of this medication intravenously initially (16.2 mmol). A subsequent dose of 1 g may be given. Electrolyte replenishment (hypomagnesemia):

Child administration

Children: The safety of this medication has not been tested.

This medication should be handled carefully when cutting the glass ampoule, as glass shards may be introduced. Extra caution is advised for use in children and the elderly. It should not be administered to patients with impaired renal function, unconscious patients, patients with high serum magnesium levels, patients with cardiac conduction disorders, and myasthenia gravis patients. Use this medication with caution in children with intestinal parasitic diseases or patients with heart disease. Gastrointestinal symptoms such as vomiting or dry mouth may occur with this medication, and in rare cases, bradycardia or conduction disorders may develop. Rapid infusion may cause flushing of the skin or peripheral vasodilation and symptoms such as headache, heavy-headedness, tremors, and paresthesia may occur. In cases of overdose, magnesium toxicity may occur, presenting as sensations of warmth, thirst, hypotension, central nervous system depression, bradycardia, or respiratory paralysis, requiring immediate treatment. Calcium may be administered intravenously as an antidote. This medication may enhance central nervous system depressant effects when used with barbiturates, narcotics, sedatives, or general anesthetics. Caution should also be exercised as co-administration with iron supplements, certain antibiotics, or sodium fluoride may reduce drug absorption. It may be administered to pregnant women with eclampsia for the life of the mother and fetus; however, it may induce decreased fetal muscle tone, reflexes, and hypotension, so fetal heart rate should be monitored continuously. This medication should not be used within two hours after delivery due to the risk of neonatal respiratory depression. Its safety during breastfeeding is not established, so administration is not recommended unless specifically required. Elderly patients may have reduced bodily functions, therefore the administration rate should be slow, and dosages should be adjusted with caution. In overdose cases, serious side effects may occur depending on serum magnesium levels, so immediate discontinuation and antidote use should be taken if symptoms occur. Administer slowly via intravenous injection at a concentration of 10% or less; caution should be used as precipitates may form when mixed with other medications. Ensure thorough disinfection of the patient’s skin and injection apparatus prior to use, and use opened solutions immediately; do not reuse any remaining solution.

Serious side effects

Conduction disorders, bradycardia, respiratory paralysis due to magnesium toxicity

Mild side effects

• Vomiting
• dry mouth
• flushing
• peripheral vasodilation
• headache
• heavy-headedness
• tremors
• paresthesia
• warmth
• thirst

This medication is sensitive to light and should be stored in a sealed container that blocks light, such as an ampoule. It can also be stored in a sealed plastic container. It is important to maintain storage temperature between 1 degree and 30 degrees Celsius.

Appearance

Brown ampoule containing a colorless and transparent liquid or injection in a colorless and transparent plastic container

Package unit

5 mL (ampoule) × 50 ampoules 20 mL (plastic ampoule) × 50 ampoules